Your session is about to expire
← Back to Search
Herbal Therapy
ArtemiCoffee for Prostate Cancer
Phase 2
Recruiting
Led By Zin Myint, MD
Research Sponsored by Zin W Myint
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Completion of localized therapy (prostatectomy or radiotherapy) for prostate adenocarcinoma (either histologically or cytologically confirmed)
Eastern Cooperative Oncology Group (ECOG) performance status ≤3
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks (baseline, 3-mos, 6-mos and post-treatment)
Awards & highlights
Study Summary
This trial will study whether Aa coffee can decrease PSA levels in men with BCR prostate cancer.
Who is the study for?
This trial is for men over 18 who've had prostate cancer treatment but now have rising PSA levels without visible cancer spread. They should be relatively healthy, with no recent hormone therapy or certain other drugs, and no serious illnesses that could affect study participation.Check my eligibility
What is being tested?
The trial tests ArtemiCoffee's ability to lower rising PSA in patients with biochemical recurrence of prostate cancer after initial treatments like surgery or radiation. It explores whether this coffee containing Artesunate can slow down the return of cancer signs.See study design
What are the potential side effects?
While specific side effects are not listed, similar herbal supplements may cause digestive upset, allergic reactions, or interact with other medications. Participants will be monitored for any adverse effects during the trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have completed treatment for prostate cancer through surgery or radiation.
Select...
I am capable of limited self-care and spend less than half of my day in bed.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks (baseline, 3-mos, 6-mos and post-treatment)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks (baseline, 3-mos, 6-mos and post-treatment)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of patients who achieve a 50% decline in PSA levels
Secondary outcome measures
Change in PSA velocity and slope from pre-treatment to post-treatment
Percentage change in serial PSA
Percentage change in serial testosterone levels
Other outcome measures
Change in plasma concentration of artemisinin and dihydroartemisinin
Trial Design
1Treatment groups
Experimental Treatment
Group I: Prostate cancer patientsExperimental Treatment1 Intervention
Men with biochemical recurrence of prostate cancer after initial local therapy.
Find a Location
Who is running the clinical trial?
Zin W MyintLead Sponsor
2 Previous Clinical Trials
85 Total Patients Enrolled
2 Trials studying Prostate Cancer
85 Patients Enrolled for Prostate Cancer
ArtemiLifeUNKNOWN
1 Previous Clinical Trials
18 Total Patients Enrolled
Zin Myint, MDPrincipal InvestigatorUniversity of Kentucky
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not taking medications like phenobarbital or rifampin.I have completed treatment for prostate cancer through surgery or radiation.I am not taking medications like nevirapine, ritonavir, or strong UGT inducers/inhibitors.My scans show cancer has spread to other parts of my body.You have a mental health condition or personal circumstances that might make it difficult for you to follow the study's rules and requirements.I have another cancer type, but it won't affect this treatment's safety or results.I do not have any active infections or uncontrolled illnesses.I have used hormone therapy for cancer in the last 3 months.I have received chemotherapy for recurring prostate cancer.I am capable of limited self-care and spend less than half of my day in bed.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Prostate cancer patients
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment for this scientific experiment still open?
"The records hosted on clinicaltrials.gov reveal that this medical trial has stopped recruiting participants as of July 25th 2022, despite being initially posted a few months prior in November 1st 2022. However, there are over 1300 other trials actively looking for volunteers at the present moment."
Answered by AI
Has the United States Food and Drug Administration authorized ArtemiCoffee?
"The safety of ArtemiCoffee has been rated 2 on our 1-3 scale since there is prior evidence confirming its security, yet no data indicating it's efficacy."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger